Non-invasive Respiratory Support in Preterm Infants (NOVEL)

Non-invasive Respiratory Support in Preterm Infants: a Multicentre Pilot Randomized Controlled Trial

Lungs of babies born early are not fully developed and they often need a machine to help them breathe. The traditional approach to provide this support is with a breathing tube passed into the windpipe. However, we know that breathing tubes can cause injury to the fragile lungs of premature babies. Providing breathing support through nose-masks instead of breathing tubes (called nasal breathing support) is becoming popular, as it is gentler on developing lungs. Doctors, in trying to limit the use of support with a breathing tube, are using many different forms of nasal breathing support. The most common form is nasal continuous positive airway pressure (CPAP) which delivers a constant pressure and the baby breathes on his on her own. However, when this strategy is no longer able to support a premature baby's breathing, the best way to provide breathing support is not known. Some doctors use a strategy called "nasal intermittent positive airway pressure" (NIPPV) which gives the baby artificial breaths through the nose-mask. Others simply increase the pressure on nasal CPAP to higher than traditional levels. In the first study of its kind, we will compare these two strategies of nasal breathing support given to premature babies.

Study Overview

• Status: Recruiting
• Conditions: Bronchopulmonary Dysplasia; Preterm Infant; Respiratory Insufficiency Syndrome of Newborn
• Intervention / Treatment: Other: Non-invasive respiratory support mode

Detailed Description

BACKGROUND:

Bronchopulmonary dysplasia (BPD) is the most common morbidity of prematurity, and affects up to 40% of all preterm infants. It is independently associated with long term pulmonary and neurodevelopmental impairment, and confers a significant cost to society. Although development of BPD is multifactorial in nature, endotracheal mechanical ventilation (EMV) is known to be a significant contributor and strategies aimed at avoiding endotracheal mechanical ventilation may indeed reduce the incidence of bronchopulmonary dysplasia.

Use of non-invasive respiratory support (NRS) has increased over the last decades in an effort to minimize dependence on endotracheal ventilation and reduce BPD in preterm neonates. Nasal continuous positive airway pressure (NCPAP) remains the prototypical form of NRS and is most commonly utilized. Another commonly used modality is non-invasive positive pressure ventilation (NIPPV) though it is often relegated as a "rescue" NRS mode following failure of NCPAP. NIPPV mimics tidal breathing by delivering "breaths" through a nasal interface at regular intervals, and results in higher mean airway pressures compared to NCPAP. Despite the increase in use of NRS and evidence from clinical studies demonstrating effectiveness in reducing BPD,results at a population level have been rather disappointing, with a recent report from the United States actually showing an increasing trend in BPD.

In recent years, in an effort to further minimize dependence on endotracheal ventilation and BPD, some new strategies in NRS use are emerging. One of these approaches is the early use of NIPPV in place of NCPAP, rather than as a rescue mode after failure of NCPAP. Two recent Cochrane reviews have evaluated NIPPV as an alternative to NCPAP, and suggested superiority over NCPAP Based on these results, a number of NICUs have started utilizing NIPPV in place of NCPAP as the default NRS mode. However, there are a number of methodological limitations of studies that were included in these reviews. First, most studies did not allow for rescue use of NIPPV in the NCPAP arms, which is not representative of current clinical practice at most NICUs. Secondly, the mean airway pressures in NIPPV vs. NCPAP were vastly different, and the question remains whether it is truly the mechanism of NIPPV or simply higher mean airway pressure that leads to the superior outcomes reported. These limitations warrant consideration because most NIPPV use is not synchronized to patients' respiratory efforts, the optimal and safe peak pressures remain unknown.

An alternative approach that has emerged in recent years is the use of high end-expiratory pressures (defined as pressures > 8 cm H2O) on NCPAP. As of 2015, use of high NCPAP pressures had only been adopted at 5 out of 28 Canadian neonatal intensive care units (NICU), and McMaster Children's Hospital NICU is currently one of only few Canadian centres employing pressures > 12 cm H2O on NCPAP. The reasons for the lack of widespread use of high end-expiratory pressures on NCPAP are unknown, but may relate to the theoretical concerns of altered systemic hemodynamics including impaired cardiac venous return, decreased venous drainage of the cerebral circulation as well as the potential for air leak syndromes such as pneumothoraces. On the other hand, such high end-expiratory pressures are very commonly and safely used during endotracheal mechanical ventilation, as well as during NIPPV. As such, the selective use of high end-expiratory pressures on NCPAP non-invasively may be quite appropriate. However, the use of high end-expiratory pressures on NCPAP is currently based on very limited evidence, and whether adopting this strategy leads to a meaningful decline in the dependence on endotracheal ventilation and/or bronchopulmonary dysplasia remains unknown. In this study, we aim to comparatively evaluate use of NIPPV vs. high end-expiratory pressures (> 8 cmH2O) on NCPAP after failure of NCPAP use at traditional pressures (≤ 8 cmH2O) among preterm infants. This will be the first prospective clinical study to evaluate high end-expiratory pressures on NCPAP, and also the first to compare NIPPV and NCPAP at equivalent mean airway pressures. If high NCPAP is shown to be as effective and safe as NIPPV, it will lead to a significant advancement in the understanding of NRS and the respiratory management of extremely preterm neonates.

OBJECTIVES AND HYPOTHESIS:

To determine the feasibility of the conduct of a larger and definitive trial comparing two NRS strategies (NIPPV vs. high NCPAP pressures) in preterm infants. Therefore to prepare for this a pilot trial is proposed. We hypothesize that the conduct of a definitive trial comparing these two NRS modes to assess clinical outcomes will be feasible.

METHODS:

Parents of all patients with gestational age < 29 weeks who do not meet any of the exclusion criteria will be approached for consent by the research assistant at the earliest opportunity. Consent will be sought within the first 72 hours. Subjects whose parents provide consent AFTER 72 days will still be eligible, as long as there is no administration of high NCPAP or NIPPV outside of randomization for greater than 4 continuous hours. A subject for whom consent is obtained from the parents will be considered an "enrolled subject". The research assistant will be responsible for indicating this by placing a laminated card at the bedside, and informing both the medical and respiratory therapy teams.

Enrolled subjects who meet NRS failure criteria despite NCPAP 8 cmH2O, or are being extubated from invasive mechanical ventilation with a mean airway pressure >/= 10 cmH2O will be eligible for randomization to either high CPAP > 8 cmH2O (experimental arm) or NIPPV (control arm). Once NRS failure criteria (indicated on bedside laminated card) and randomization eligibility is confirmed, the subject will be randomized using an electronic web-based secure platform (REDCap). An enrolled subject who gets randomized to one of the two arms will be considered a "randomized subject". A study initiation form will be completed by the research team within 24 hours of randomization, and a new laminated card indicating arm of randomization and extubation criteria will replace the enrollment card. This form will include demographic data about the subject, the NRS failure criteria that was met which led to randomization, and the suspected underlying pathophysiological mechanism for NRS failure.

Guidelines for initiation and recommended increments of both high CPAP and NIPPV will be provided, with a view towards maintaining similar mean airway pressures between the two modes (which will also be placed at patient bedside in randomized subjects). Given the existing variability of practice in NRS application and lack of evidence-based guidelines, the strategies will NOT provide guidance with regards to day-to-day changes in settings or modalities, but rather provide only ceiling limits and maximum allowed pressures for each NRS mode. Interfaces that will be allowed include either nasal masks or short bi-nasal prongs, as well as non-occlusive prongs (e.g. RAM cannula). However, ceiling limits and maximum allowed pressures for each NRS mode will be provided, as delineated below:

• High CPAP - Maximum PEEP: 15 cmH2O
• NIPPV - Maximum (set) PIP: 25 cmH2O; AND/OR Maximum (set) PEEP: 10 cmH2O; AND/OR Maximum (calculated) MAP: 15 cmH2O

If NRS failure criteria are met despite escalating settings (with a strongly suggested - but not mandated - minimum MAP of 12 cmH2O) whether either randomized arm of high NCPAP or NIPPV, the clinician will have one of following three options:

• Intubation and endotracheal mechanical ventilation
• Escalation of settings within the randomized arm beyond the aforementioned ceiling limit - will still be considered failure of assigned mode
• Use of an alternate mode of NRS (NIV-NAVA or NIHFV) - but no crossover

Of note, the maximum recommended settings for each NRS mode need not be reached before decision to intubate a subject, at the medical team's discretion. Furthermore, the NRS strategy corresponding to the randomization arm reflects use of NRS at any and all times after randomization until a randomized subject is discharged or transferred. The decision to wean down to traditional NCPAP levels from either arm will be at discretion of the medical team. Finally, subjects randomized to a particular strategy will NOT be allowed to cross-over to the other arm until the first intubation. Patients may be pulled out from the study protocol only at the discretion of the attending medical physician following the first intubation, and the reason must be discussed in advance with the PI (A.M.). A customized protocol violation form will then be completed by the attending physician, facilitated by the research assistant.

Two major forms of protocol violations will be tracked prospectively (by research coordinator):

1. Use of NIPPV or high CPAP >4 hours in an enrolled patient outside of randomization. Such patients will not be included in any further analysis of clinical outcomes, but will count towards feasibility outcome.
2. A patient with protocol violation related to cross-over; such a patient will be treated as intention-to-treat for clinical outcomes, but a set of sensitivity analyses excluding such patients (i.e. those that underwent protocol violation) will be conducted (see section below on Sensitivity Analyses).

Assessment of cerebral and renal regional perfusion will be performed using near-infrared spectroscopy (NIRS) for all subjects (at the primary study site only) at time of randomization. At the time an enrolled subject meets NRS failure criteria, the NIRS leads will be placed and recording will be initiated. Perfusion will be assessed immediately prior to and continuously for up to 7 days post-randomization (or intubation if sooner that 7 days). This will be conducted by the research assistant during office hours and the respiratory therapist at night.

At the end of the study period, relevant demographic data and outcome variables for all randomized subjects will be extracted from the local Canadian Neonatal Network (CNN) database (or other equivalent local database) and from patient charts/electronic records by the research coordinator using a customized data collection form.

DATA ANALYSIS, STATISTICS AND SAMPLE SIZE CALCULATIONS

All randomized patients will be analyzed using intention-to-treat principle. Mean (SD) or Median (IQR) will be reported for continuous variables depending on normality of data, and percentages will be reported for categorical variables. T-test (or Wilcoxon rank sum test for non-normally distributed variables) and Chi-square test (or Fisher's exact test as appropriate) will be used to compare continuous and categorical variables, respectively. All analyses will be performed using SAS version 9.4.

Sensitivity analyses (for only the main secondary outcome) based on the following variables:

The following 4 sets of sensitivity analyses will be conducted for secondary outcome #1 only by exclusion of:

1. Patients with at least one protocol violation due to crossover to alternate study arm within 1st week post-randomization
2. Patients for whom a minimum MAP of 12 cmH2O was NOT utilized prior to non-invasive support failure on at least one occasion within 1st week post-randomization
3. Patients who failed post-randomization non-invasive support due to a non-respiratory pathology on at least one occasion within 1st week post-randomization
4. Patients placed on study intervention using RAM cannula at time of randomization

We will only perform sensitivity analyses if any one or more of the above results in exclusion of ≥20% of the randomized cohort.

Regression analyses: No regression analyses are planned a-priori for this pilot trial.

Regional perfusion data using NIRS (from participant data at primary study site only) will be compared within each randomization arm (immediately prior to and 2 hours post-randomization) as well as between the two randomization arms 2 hours-post randomization using paired t-test and unpaired t-tests, respectively.

A convenience sample of 100 subjects (40 at the lead institution and 20 per site at the other 3 centres) will be chosen for the purposes of this pilot trial. Analysis of secondary outcomes from this pilot study will help inform the design and sample size for a definitive trial comparing high CPAP and NIPPV. The feasibility outcome goals were used to determine the sample size, based on methods described by Thabane et al.

DATA SAFETY AND MONITORING BOARD (DSMB): A DSMB will perform two reviews - one following the transition of the first phase of the study (30 randomized patients) and prior to commencement of the second phase, with a second review occurring after 40 patients have been randomized (70 total) in the second phase.

Appendix: NRS Failure Criteria

• FiO2 >50% or rise in FiO2 >20% in ≤12 hours
• High CO2 with pH <7.20 (respiratory acidosis) on arterial or capillary blood gas

• Increased work of breathing (with RR >80 bpm) for at least 10 minutes

  o Modified DOWNES' score to be completed in real time to objectively describe components of increased work of breathing

• Apnea/Desaturation/Bradycardia spells (>1 requiring bagging in a 4 hour period or >4/hour requiring moderate stimulation x 4 hours)
• Need for intubation related to non-respiratory pathology including but not limited to necrotizing enterocolitis, septic deterioration and hemodynamically significant ductus arteriosus where none of the above failure criteria are applicable [this option only applicable to post-randomization NRS failure]

• Study Type: Interventional
• Enrollment (Anticipated): 100
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Canada
  • Ontario
    • Hamilton, Ontario, Canada, L8S4K1
      • Recruiting
      • McMaster Children's Hospital
      • Contact: Amit Mukerji, MD; Phone Number: 76486 9055212100; Email: mukerji@mcmaster.ca

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 3 days and older (ADULT, OLDER_ADULT, CHILD)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria: All preterm neonates with gestational age < 29 weeks with a chronological age of at least 72 hours admitted to one of three participating NICUs (McMaster Children's Hospital, Royal Alexandra Hospital, and Westmead Hospital); whose families have consented to study participation; and who do not meet any of the following exclusion criteria:

1. Major upper airway malformation (cleft lip/palate, severe micro-retrognathia, congenital tracheal stenosis or vascular ring, and neck mass/cystic hygroma)
2. Major (non-airway) congenital abnormality not-yet repaired (congenital diaphragmatic hernia, abdominal wall defect, and tracheo-esophgeal fistulas)
3. Suspected or confirmed chromosomal/genetic abnormality
4. Administration of high NCPAP or NIPPV outside of randomization for greater than 4 continuous hours.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: High NCPAP; Administration of high NCPAP (> 8 cmH2O) following either failure of traditional NCPAP pressures (≤ 8 cmH2O) OR post-extubation from high endotracheal mechanical ventilation settings (defined as mean airway pressure ≥10 cmH2O)	Other: Non-invasive respiratory support mode; A mode of providing respiratory support via nasal masks or prongs
ACTIVE_COMPARATOR: NIPPV; Administration of NIPPV following either failure of traditional NCPAP pressures (≤ 8 cmH2O) OR post-extubation from high endotracheal mechanical ventilation settings (defined as mean airway pressure ≥10 cmH2O)	Other: Non-invasive respiratory support mode; A mode of providing respiratory support via nasal masks or prongs

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Ability to enroll a minimum of 10% of all eligible neonates per year at each site	Ability to enroll a minimum of 30% of all admitted neonates < 29 weeks GA who do not meet exclusion criteria AND ability to randomize a minimum of 33% of all enrolled patients per year at each site [i.e. randomize a minimum of 10% of all eligible neonates]	Through study completion (total 42 months)
Fewer than 20% randomized subjects with protocol violations in High CPAP arm	Defined as any use of NIPPV	Through study completion (total 42 months)
Fewer than 20% randomized subjects with protocol violations in NIPPV arm	Defined as any use of high NCPAP > 8 cmH2O	Through study completion (total 42 months)
Fewer than 20% of enrolled (consented, but pre-randomization) subjects with protocol violations	Defined as post-consent initiation of high NCPAP or NIPPV for >4 hours without randomization	Through study completion (total 42 months)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Failure of assigned NRS mode within 7 days post-randomization	Criteria for failure of assigned NRS mode resulting in one of: (A) Intubation and mechanical ventilation; (B) Escalation beyond maximum allowed settings within the intervention arm; or (C) Use of an alternate NRS strategy not being studied in this RCT (e.g. NIV-NAVA or NIHFV).	7 days post-randomization
Need for endotracheal ventilation at 72 hours and 7 days post-randomization	as above	72 hours and 7 days post-randomization
Pre-discharge, in-hospital mortality	as above	Through to completion of initial hospitalization for each subject (estimated 40-44 weeks postmenstrual age)
Bronchopulmonary dysplasia (BPD, based on NICHD criteria) (16) among survivors only	as above	until 36 weeks postmenstrual age
Composite of pre-discharge mortality or BPD (latter as defined above)	as above	Through to completion of initial hospitalization for each subject (estimated 40-44 weeks postmenstrual age)
Duration (days) of supplemental oxygen days	as above (assessed only post randomization)	Through to completion of initial hospitalization for each subject (estimated 40-44 weeks postmenstrual age)
Duration (days) of any respiratory support	as above (assessed only post randomization)	Through to completion of initial hospitalization for each subject (estimated 40-44 weeks postmenstrual age)
Duration (days) of endotracheal mechanical ventilation	as above (assessed only post randomization)	Through to completion of initial hospitalization for each subject (estimated 40-44 weeks postmenstrual age)
Proportion of infants on any endotracheal mechanical ventilation	as above (assessed only post randomization)	Through to completion of initial hospitalization for each subject (estimated 40-44 weeks postmenstrual age)
Duration (days) of initial hospitalization at NICU	as above	Through to completion of initial hospitalization for each subject (estimated 40-44 weeks postmenstrual age)
Postmenstrual age (weeks) at onset of oral feeding (defined as not requiring gavage)	as above	Through to completion of initial hospitalization for each subject (estimated 40-44 weeks postmenstrual age)
Air leak syndromes (n, defined as pneumothorax, pneumomediastinum, and/or pulmonary interstitial emphysema as defined on radiographic report)	as above (assessed only post randomization)	Through to completion of initial hospitalization for each subject (estimated 40-44 weeks postmenstrual age)
Spontaneous intestinal perforations (n, defined on radiographic report)	as above (assessed only post randomization)	Through to completion of initial hospitalization for each subject (estimated 40-44 weeks postmenstrual age)
Cerebral and renal regional perfusion (using near-infrared spectroscopy)	as above	7 days post randomization (or intubation, if sooner)
• Need for endotracheal mechanical ventilation within 7 days following failure of the post-randomization assigned mode of NRS	as above	7 days following failure of assigned mode through randomization

Collaborators and Investigators

• Sponsor: McMaster Children's Hospital
• Collaborators: The Physicians' Services Incorporated Foundation; Hamilton Academic Health Sciences Organization; Hamilton Health Sciences Foundation - New Investigator Fund

Study record dates

Study Major Dates

• Study Start (ACTUAL): May 15, 2018
• Primary Completion (ANTICIPATED): November 30, 2023
• Study Completion (ANTICIPATED): December 31, 2023

Study Registration Dates

• First Submitted: April 11, 2018
• First Submitted That Met QC Criteria: April 18, 2018
• First Posted (ACTUAL): April 30, 2018

Study Record Updates

• Last Update Posted (ACTUAL): December 16, 2022
• Last Update Submitted That Met QC Criteria: December 14, 2022
• Last Verified: December 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Respiration Disorders; Lung Diseases; Infant, Newborn, Diseases; Pregnancy Complications; Obstetric Labor Complications; Obstetric Labor, Premature; Lung Injury; Infant, Premature, Diseases; Ventilator-Induced Lung Injury; Respiratory Insufficiency; Premature Birth; Bronchopulmonary Dysplasia
• Other Study ID Numbers: 2018-2113

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No